Qualigen to sell SARS-CoV-2 test in U.S. in July

LabPulse.com staff writers
Jun 30, 2020
2019 11 08 17 54 6978 News Ball 400

Qualigen Therapeutics notified the U.S. Food and Drug Administration (FDA) that it will begin selling its SARS-CoV-2 antibody test in the U.S. this month.

The notification allows Qualigen to sell its FastPack SARS-CoV-2 immunoglobulin G (IgG) test while the FDA considers granting its request for an emergency use authorization for the product. The company expects sales and shipments of the test to start in mid-July.

The test is a chemiluminescent microparticle test intended for the qualitative detection of SARS-CoV-2 IgG antibodies in blood to identify individuals with an adaptive immune response to the virus that causes COVID-19. Results are delivered in fewer than 10 minutes, according to Qualigen.

Latest in Emergency Use Authorization
Monkeypox Virus Social
Cue Health receives FDA emergency use authorization for molecular mpox test
March 20, 2023
Covid Test Preschool Social
Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases
February 27, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
May 11, 2023
Fda Button Social
FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses
February 24, 2023
Related Stories
2020 06 17 20 35 0417 Covid 19 Antibody 400
Emergency Use Authorization
ZRT launches dried blood antibody tests for SARS-CoV-2
2019 08 09 22 20 6739 Beckman Coulter Aacc 2019 400
CE mark
Beckman Coulter secures EUA for SARS-CoV-2 test
2020 05 05 21 16 5661 Coronavirus Global Spread 400
Regulatory Approval
World market outlook: COVID-19 testing evolves rapidly, lessons sink in
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Emergency Use Authorization
Cue Health receives FDA emergency use authorization for molecular mpox test
The test demonstrated high accuracy in clinical trials, achieving 100% concordance with the Center for Disease Control and Prevention’s (CDC's) mpox test on the samples tested, Cue Health said.
March 20, 2023
Monkeypox Virus Social
Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases
The development of the rapid antigen test was funded under an $11.8 million contract through the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative.
February 27, 2023
Covid Test Preschool Social
Lucira Health files for bankruptcy despite receiving FDA green light
The firm is seeking a strategic or financial partner for the resumption of manufacturing and development of additional home diagnostic testing products.
February 27, 2023
Business Deal Corporate Social
FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses
In people with symptoms, the Lucira COVID-19 & Flu Test correctly identified 99.3% of negative and 90.1% of positive influenza A samples; 100% of negative and 88.3% of positive COVID-19 samples; and 99.9% of negative influenza B samples, the FDA said.
February 24, 2023
Fda Button Social
FDA grants emergency use authorization for Anavasi LAMP-based COVID-19 test, detector
Anavasi said its point-of-care platform will enable the rapid development of tests to detect viral and bacterial targets, including influenza, respiratory syncytial virus (RSV), and sexual health-related strains, among others.
February 13, 2023
Virus Coronavirus Covid 19 Social
FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care
The Xpert Mpox test is a real-time polymerase chain reaction assay to detect Mpox virus DNA in lesion swab specimens from individuals suspected of monkeypox by their healthcare provider.
February 10, 2023
3 D Monkeypox Infecting Cell Social
BD nabs FDA authorization for SARS-CoV-2, influenza A/B, RSV combination test
The test uses a single nasal or nasopharyngeal swab sample to identify and distinguish whether a patient has COVID-19, the flu, RSV, or some combination of the three, with results available in two hours.
February 8, 2023
Quality Check Mark Social
LumiraDx obtains FDA authorization for test to detect flu A, flu B, SARS-CoV-2
The test leverages a single-step direct method for nucleic acid extraction and amplification on validated open RT-PCR instruments.
February 7, 2023
Covid 19 Antibody Social
Lucira Health applies for FDA Emergency Use Authorization of over-the-counter COVID-19, flu A, flu B molecular test
The single-use test fits in the palm of the hand, runs on two AA batteries, and with one shallow nasal swab provides a positive or negative result for COVID-19, flu A, or flu B in less than 30 minutes.
January 3, 2023
Sars Co V 2 Covid 19 Mask Pixabay Social
Visby Medical receives FDA Emergency Use Authorization for respiratory test in CLIA-waived settings
The Respiratory Health Test is a rapid PCR device that detects and differentiates upper respiratory infections caused by influenza A & B and SARS-CoV-2.
January 3, 2023
Fda Button Social
CorDx receives FDA Emergency Use Authorization for COVID-19 antigen test
The COVID-19 Ag lateral flow immunoassay provides qualitative detection of the nucleocapsid protein antigen from the SARS-CoV-2 virus, providing a result in 10 minutes.
December 1, 2022
Covid Diagnostic Test Kit Social
Roche obtains FDA authorization for monkeypox test on high-throughput MDx system
Roche's Cobas MPXV test targets two different regions of the MPXV genome which are both less prone to mutations than other parts of the genome, the firm said.
November 16, 2022
Fda Button Social
Page 1 of 14
Next Page